Myovant Sciences Ltd (MYOV) Gross Profit Margin starting from the third quarter 2022 to third quarter 2021, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Myovant Sciences Ltd   (NYSE: MYOV)


Myovant Sciences Ltd 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYOV Gross Profit Margin (Dec 31 2022)
Q3 		(Sep 30 2022)
Q2 		(Jun 30 2022)
Q1 		(Mar 31 2022)
Q4 		(Dec 31 2021)
Q3
Y / Y Revenue Change 84.11 %
Seq. Revenue Change -4.38 %
Revenue In Millions $100.23
Gross Profit Margin 92.6 %
Gross Profit Margin Total Ranking # 251
Gross Profit In Millions $92.81
Y / Y Gross Profit Change 84.89 %
Seq. Gross Profit Change -7.08 %


Commenting Third Quarter 2022 Gross Profit Margin
Myovant Sciences Ltd experienced contraction in Gross Profit by -7.08 % to $100 millions and Revenue by -4.38 %, while Gross Profit Margin fell to 92.6 %, below company*s average Gross Profit Margin.


Observing third quarter 2022 results within Major Pharmaceutical Preparations industry 28 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 204 to 251.
Learn about Gross Margin
MYOV's Gross Profit Margin third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 42
Overall # 245

Gross Profit Margin Statistics
High Average Low
98.78 % 95.31 % 92.21 %
(Mar 31 2021)   (Dec 31 2021)


MYOV Gross Income Trends • More of MYOV's Profitabilty Ratios • MYOV Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
MYOV's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
MYOV's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for MYOV's Competitors
Gross Profit Margin Profit Margin for Myovant Sciences Ltd 's Suppliers
Gross Profit Margin Profit Margin for MYOV's Customers

You may also want to know
MYOV's Annual Growth Rates MYOV's Profitability Ratios MYOV's Asset Turnover Ratio MYOV's Dividend Growth
MYOV's Roe MYOV's Valuation Ratios MYOV's Financial Strength Ratios MYOV's Gross Profit Growth
MYOV's Roa MYOV's Inventory Turnover Ratio MYOV's Growth Rates MYOV's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Gross Profit MarginDec 31 2022 MRQ Gross ProfitDec 31 2022 MRQ Revenue
Immuneering Corporation  100.00 %$ 0.000  Millions$ 0.000  Millions
Macrogenics Inc   99.84 %$ 72.983  Millions$ 73.099  Millions
Ptc Therapeutics inc   99.70 %$ 166.913  Millions$ 167.413  Millions
Uniqure N v   99.57 %$ 102.306  Millions$ 102.745  Millions
Pasithea Therapeutics Corp   99.46 %$ 0.239  Millions$ 0.241  Millions
Rigel Pharmaceuticals Inc  99.33 %$ 50.936  Millions$ 51.278  Millions
2seventy Bio Inc   99.16 %$ 55.703  Millions$ 56.177  Millions
Cormedix Inc   98.63 %$ 0.029  Millions$ 0.030  Millions
Corcept Therapeutics Inc  98.56 %$ 101.576  Millions$ 103.056  Millions
Acadia Pharmaceuticals Inc   98.23 %$ 134.076  Millions$ 136.490  Millions
Calliditas Therapeutics Ab  98.11 %$ 84.675  Millions$ 86.309  Millions
Adc Therapeutics Sa  97.82 %$ 205.329  Millions$ 209.908  Millions
Galapagos Nv  97.61 %$ 552.385  Millions$ 565.914  Millions
Ionis Pharmaceuticals Inc   97.57 %$ 148.204  Millions$ 151.890  Millions
Travere Therapeutics Inc   96.91 %$ 54.140  Millions$ 55.868  Millions
Bioxcel Therapeutics Inc   96.22 %$ 0.229  Millions$ 0.238  Millions
Whitehawk Therapeutics Inc   95.75 %$ 5.005  Millions$ 5.227  Millions
Ligand Pharmaceuticals Incorporated  95.50 %$ 25.827  Millions$ 27.045  Millions
Aurinia Pharmaceuticals Inc   95.21 %$ 27.073  Millions$ 28.435  Millions
Sage Therapeutics Inc   95.01 %$ 2.721  Millions$ 2.864  Millions
Ultragenyx Pharmaceutical Inc   94.85 %$ 98.029  Millions$ 103.348  Millions
Xbiotech Inc   94.67 %$ 0.284  Millions$ 0.300  Millions
Cti Biopharma Corp   94.46 %$ 19.916  Millions$ 21.083  Millions
Quantum Cyber N v   94.24 %$ 0.182  Millions$ 0.193  Millions
Y mabs Therapeutics inc   93.57 %$ 29.426  Millions$ 31.447  Millions
Zevra Therapeutics Inc   93.49 %$ 2.168  Millions$ 2.319  Millions
Ardelyx inc   92.84 %$ 41.016  Millions$ 44.178  Millions
Ocular Therapeutix Inc   92.81 %$ 13.064  Millions$ 14.076  Millions
Myovant Sciences Ltd   92.60 %$ 92.811  Millions$ 100.229  Millions
Bellicum Pharmaceuticals Inc   92.40 %$ 0.462  Millions$ 0.500  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.